Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MMP8 | P22894 | 2/20 | 0.57 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27574237 | 0.84 | SMN1; SMN2 (0.68) | SMN1; SMN2MMP8PIN1KMT2AMEN1 | |
| SCHEMBL4047441 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2MMP8PIN1KMT2AMEN1 | |
| SCHEMBL5225218 | 0.83 | KMT2A (0.62) | KMT2AMEN1LMNATSHR | |
| SCHEMBL1712333 | 0.83 | KMT2A (0.62) | KMT2AMEN1LMNATSHR | |
| SCHEMBL8273800 | 0.83 | KMT2A (0.62) | KMT2AMEN1LMNATSHR | |
| SCHEMBL24661545 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2MMP8PIN1KMT2AMEN1 | |
| SCHEMBL3937562 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2MMP8PIN1KMT2AMEN1 | |
| SCHEMBL11841853 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2MMP8PIN1KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL5223983 | 0.81 | KMT2A (0.60) | KMT2AMEN1LMNATSHR | |
| SCHEMBL28510565 | 0.81 | SMN1; SMN2 (0.61) | SMN1; SMN2MMP8PIN1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| WO-2005058892-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | SMN1; SMN2 3929/4885MMP8 1868/4885PIN1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.